JP2022544652A5 - - Google Patents
Info
- Publication number
- JP2022544652A5 JP2022544652A5 JP2022508754A JP2022508754A JP2022544652A5 JP 2022544652 A5 JP2022544652 A5 JP 2022544652A5 JP 2022508754 A JP2022508754 A JP 2022508754A JP 2022508754 A JP2022508754 A JP 2022508754A JP 2022544652 A5 JP2022544652 A5 JP 2022544652A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- case
- carbon
- bonded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025128566A JP2025173509A (ja) | 2019-08-14 | 2025-07-31 | 核酸の送達のための改善された脂質ナノ粒子 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886894P | 2019-08-14 | 2019-08-14 | |
| US62/886,894 | 2019-08-14 | ||
| PCT/US2020/046407 WO2021030701A1 (en) | 2019-08-14 | 2020-08-14 | Improved lipid nanoparticles for delivery of nucleic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025128566A Division JP2025173509A (ja) | 2019-08-14 | 2025-07-31 | 核酸の送達のための改善された脂質ナノ粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544652A JP2022544652A (ja) | 2022-10-20 |
| JP2022544652A5 true JP2022544652A5 (https=) | 2023-08-21 |
| JP7753190B2 JP7753190B2 (ja) | 2025-10-14 |
Family
ID=72322523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508754A Active JP7753190B2 (ja) | 2019-08-14 | 2020-08-14 | 核酸の送達のための改善された脂質ナノ粒子 |
| JP2025128566A Pending JP2025173509A (ja) | 2019-08-14 | 2025-07-31 | 核酸の送達のための改善された脂質ナノ粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025128566A Pending JP2025173509A (ja) | 2019-08-14 | 2025-07-31 | 核酸の送達のための改善された脂質ナノ粒子 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20230097090A1 (https=) |
| EP (2) | EP4013385B1 (https=) |
| JP (2) | JP7753190B2 (https=) |
| KR (1) | KR20220053599A (https=) |
| CN (1) | CN114901253A (https=) |
| AU (1) | AU2020328596B2 (https=) |
| BR (1) | BR112022002708A2 (https=) |
| CA (1) | CA3150458A1 (https=) |
| CL (1) | CL2022000351A1 (https=) |
| CO (1) | CO2022002685A2 (https=) |
| CR (1) | CR20220108A (https=) |
| DE (1) | DE112020003843T5 (https=) |
| DK (1) | DK4013385T3 (https=) |
| DO (1) | DOP2022000038A (https=) |
| EC (1) | ECSP22018209A (https=) |
| ES (2) | ES2918001R1 (https=) |
| FI (1) | FI4013385T3 (https=) |
| GB (1) | GB2600859B (https=) |
| GE (2) | GEP20257820B (https=) |
| HR (1) | HRP20241255T1 (https=) |
| HU (1) | HUE068356T2 (https=) |
| IL (1) | IL290477A (https=) |
| JO (1) | JOP20220037A1 (https=) |
| LT (1) | LT4013385T (https=) |
| MX (2) | MX2022001720A (https=) |
| PE (1) | PE20220968A1 (https=) |
| PH (1) | PH12022550363A1 (https=) |
| PL (1) | PL4013385T3 (https=) |
| PT (1) | PT4013385T (https=) |
| SI (1) | SI4013385T1 (https=) |
| UA (1) | UA129330C2 (https=) |
| WO (1) | WO2021030701A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| HRP20240586T1 (hr) | 2018-10-09 | 2024-07-19 | The University Of British Columbia | Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| EP3876999A4 (en) | 2018-11-09 | 2022-08-31 | Arbutus Biopharma Corporation | NEGATIVELY CHARGED PEG-LIPID CONJUGATES |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| ES3054438T3 (en) | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4228658A4 (en) | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| CN113402404B (zh) * | 2021-04-30 | 2022-03-11 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| KR20240008872A (ko) * | 2021-05-06 | 2024-01-19 | 아크투루스 쎄라퓨틱스, 인크. | Rna 전달을 위한 이온화 가능한 양이온성 지질 |
| CN115385820B (zh) * | 2021-05-09 | 2025-04-29 | 英维沃生物科技(苏州)有限公司 | 阳离子脂质及其应用 |
| EP4310071A4 (en) * | 2021-05-28 | 2024-11-20 | Beijing Tricisionbio Therapeutics Inc. | LIPID COMPOUND AND USE THEREOF IN THE ADMINISTRATION OF NUCLEIC ACID |
| CN113403313B (zh) * | 2021-06-23 | 2022-08-19 | 北京理工大学 | 一种特异识别人PLK1位点的sgRNA、质粒、纳米复合物和应用 |
| WO2023273364A1 (zh) * | 2021-06-30 | 2023-01-05 | 天津键凯科技有限公司 | 聚乙二醇脂质及其应用 |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN115403761B (zh) * | 2021-07-23 | 2025-04-25 | 天津键凯科技有限公司 | 一种多元甘醇修饰的脂质化合物及其制备方法和应用 |
| CN115710191B (zh) * | 2021-08-23 | 2025-06-10 | 广州谷森制药有限公司 | 阳离子脂质化合物 |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| CN115869262A (zh) * | 2021-09-27 | 2023-03-31 | 广州谷森制药有限公司 | 新型peg脂质化合物、其制备方法、组合物及应用 |
| AR127312A1 (es) * | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
| CN117440943B (zh) * | 2021-10-15 | 2025-09-30 | 厦门赛诺邦格生物科技股份有限公司 | 含氮的阳离子脂质及其应用 |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| KR20240141231A (ko) * | 2021-11-11 | 2024-09-26 | 오하이오 스테이트 이노베이션 파운데이션 | 아미노 지질 화합물을 포함하는 조성물과 이의 제조 및 사용 방법 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CN114044741B (zh) * | 2022-01-13 | 2022-04-15 | 北京悦康科创医药科技股份有限公司 | 一种阳离子脂质化合物、包含其的组合物及用途 |
| TW202330457A (zh) * | 2022-01-19 | 2023-08-01 | 大陸商蘇州艾博生物科技有限公司 | 脂質化合物和脂質奈米顆粒組合物 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN116969851A (zh) * | 2022-04-29 | 2023-10-31 | 北京剂泰医药科技有限公司 | 可电离脂质化合物 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| US20250161432A1 (en) * | 2022-06-14 | 2025-05-22 | Highfield Biopharmaceuticals Corporation | Cationic lipid compound, and preparation method therefor and use thereof |
| CN114989182B (zh) * | 2022-06-23 | 2023-06-23 | 尧唐(上海)生物科技有限公司 | 脂质化合物、包含其的组合物及应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN121930111A (zh) * | 2022-07-19 | 2026-04-28 | 深圳深信生物科技有限公司 | 氨基脂质化合物、其制备方法和应用 |
| WO2024022263A1 (zh) * | 2022-07-25 | 2024-02-01 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
| WO2024031051A1 (en) * | 2022-08-05 | 2024-02-08 | Life Technologies Corporation | Lipids for nucleic acid delivery |
| JP2025530171A (ja) * | 2022-09-07 | 2025-09-11 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤で使用するための脂質 |
| EP4585586A4 (en) * | 2022-09-09 | 2025-12-03 | Xiamen Sinopeg Biotech Co Ltd | CARBON CORE CATIONIC LIPID |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| CN115417779B (zh) * | 2022-11-03 | 2023-06-16 | 北京华芢生物技术有限公司 | 可离子化的阳离子脂c6-a1及由其组成的纳米脂质体颗粒 |
| CN115417780B (zh) * | 2022-11-04 | 2023-06-20 | 北京华芢生物技术有限公司 | 可离子化的阳离子脂c5-a2及由其组成的纳米脂质体颗粒 |
| WO2024119098A1 (en) * | 2022-12-02 | 2024-06-06 | Prime Medicine, Inc. | Lipid nanoparticle (lnp) delivery systems and formulations |
| EP4637718A1 (en) * | 2022-12-21 | 2025-10-29 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticles comprising sterol-modified phospholipids |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| CN118666726A (zh) * | 2023-03-17 | 2024-09-20 | 尧唐(上海)生物科技有限公司 | 递送治疗剂的脂质化合物及其制备方法与应用 |
| WO2024226779A1 (en) * | 2023-04-26 | 2024-10-31 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| CN117384055B (zh) * | 2023-04-27 | 2024-11-19 | 仁景(苏州)生物科技有限公司 | 用于递送治疗剂的可电离脂质及其用途 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| CN116891423B (zh) * | 2023-07-07 | 2024-03-01 | 荣灿生物医药技术(上海)有限公司 | 脂质化合物、组合物及其制备方法和应用 |
| CN119791061A (zh) * | 2023-10-11 | 2025-04-11 | 中国人民解放军军事科学院军事医学研究院 | 一种甲型肝炎病毒感染动物模型的构建方法及其用途 |
| US20250161227A1 (en) | 2023-11-17 | 2025-05-22 | Acuitas Therapeutics, Inc. | Pegylated lipids |
| WO2025128696A1 (en) | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025132122A1 (en) | 2023-12-13 | 2025-06-26 | Berlin Institute Of Health | Methods of delivering therapeutics using lipid nanoparticles |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025133105A1 (en) * | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| WO2025140421A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京剂泰医药科技有限公司 | 可电离脂质化合物及其在递送核酸疫苗中的用途 |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025174858A1 (en) | 2024-02-15 | 2025-08-21 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025184508A1 (en) | 2024-03-01 | 2025-09-04 | Acuitas Therapeutics, Inc. | Materials and methods for encapsulating therapeutics in lipid nanoparticles |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| WO2025217264A1 (en) | 2024-04-10 | 2025-10-16 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| CN118319880B (zh) * | 2024-04-15 | 2025-02-07 | 荣灿生物医药技术(上海)有限公司 | 靶向肺部高效递送核酸的脂质纳米颗粒、吸入式制剂及应用 |
| WO2025230906A1 (en) * | 2024-04-29 | 2025-11-06 | Saliogen Therapeutics, Inc. | Lipid nanoparticle (lnp) formulations |
| WO2025231114A1 (en) | 2024-05-01 | 2025-11-06 | Acuitas Therapeutics, Inc. | Method of using lipid nanoparticles for intramuscular delivery |
| WO2025240833A1 (en) | 2024-05-17 | 2025-11-20 | Acuitas Therapeutics, Inc. | Galnac lipid compounds for use in lipid nanoparticles |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026035680A1 (en) | 2024-08-06 | 2026-02-12 | Kernal Biologics, Inc. | Compositions and methods for delivery of agents |
| CN119431176B (zh) * | 2024-11-05 | 2026-02-13 | 汉信生物科技(苏州)有限公司 | 一种可电离阳离子脂质及其制备方法和应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| AU637800B2 (en) | 1989-08-31 | 1993-06-10 | City Of Hope | Chimeric dna-rna catalytic sequences |
| US6365730B1 (en) | 1990-06-19 | 2002-04-02 | Gene Shears Pty. Limited | DNA-Armed ribozymes and minizymes |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5591317A (en) | 1994-02-16 | 1997-01-07 | Pitts, Jr.; M. Michael | Electrostatic device for water treatment |
| US5631359A (en) | 1994-10-11 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | Hairpin ribozymes |
| US6197553B1 (en) | 1994-07-15 | 2001-03-06 | Merck & Co., Inc. | Method for large scale plasmid purification |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5747470A (en) | 1995-06-07 | 1998-05-05 | Gen-Probe Incorporated | Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| JP4119607B2 (ja) | 1997-08-15 | 2008-07-16 | チッソ株式会社 | 多分散性プロピレン重合体およびその製造方法 |
| CA2321837C (en) | 1998-02-03 | 2011-08-16 | Inex Pharmaceuticals Corporation | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
| EP1412065A2 (en) | 2001-07-27 | 2004-04-28 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| US6927663B2 (en) | 2003-07-23 | 2005-08-09 | Cardiac Pacemakers, Inc. | Flyback transformer wire attach method to printed circuit board |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| AU2006279906B2 (en) | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2007095387A2 (en) | 2006-02-17 | 2007-08-23 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| AU2007299705B2 (en) | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| US20130037977A1 (en) | 2010-04-08 | 2013-02-14 | Paul A. Burke | Preparation of Lipid Nanoparticles |
| US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| KR101761388B1 (ko) | 2010-07-30 | 2017-07-25 | 큐어백 아게 | 트랜스펙션 및 면역 자극을 위한 이황화-크로스링크된 양이온 성분 및 핵산의 복합체 |
| WO2012024526A2 (en) | 2010-08-20 | 2012-02-23 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| EP3456317B1 (en) * | 2011-09-27 | 2025-09-24 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| US8762704B2 (en) | 2011-09-29 | 2014-06-24 | Apple Inc. | Customized content for electronic devices |
| EP3485875A1 (en) | 2011-11-04 | 2019-05-22 | Nitto Denko Corporation | Single use system for sterelily producing lipid-nucleic acid particles |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| AU2012347605B2 (en) | 2011-12-07 | 2017-09-21 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| JP6620093B2 (ja) * | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| WO2017070624A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| CA3040337A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| EP3532103B1 (en) * | 2016-10-26 | 2025-12-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| AU2017374042C1 (en) * | 2016-12-09 | 2024-07-11 | Acuitas Therapeutics, Inc. | Delivery of target specific nucleases |
| CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| WO2019089828A1 (en) * | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| SI3703658T1 (sl) | 2017-10-31 | 2022-09-30 | Astrazeneca Ab | Lipidni nanodelci za dostavljanje spremenjene RNA, ki kodira polipeptid VEGF-A |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| PT3908568T (pt) | 2019-01-11 | 2024-09-30 | Acuitas Therapeutics Inc | Lípidos para a administração de agentes ativos por nanopartículas lipídicas |
-
2020
- 2020-08-14 CN CN202080072049.1A patent/CN114901253A/zh active Pending
- 2020-08-14 WO PCT/US2020/046407 patent/WO2021030701A1/en not_active Ceased
- 2020-08-14 GB GB2201685.1A patent/GB2600859B/en active Active
- 2020-08-14 MX MX2022001720A patent/MX2022001720A/es unknown
- 2020-08-14 AU AU2020328596A patent/AU2020328596B2/en active Active
- 2020-08-14 ES ES202290010A patent/ES2918001R1/es active Pending
- 2020-08-14 PT PT207651217T patent/PT4013385T/pt unknown
- 2020-08-14 DE DE112020003843.2T patent/DE112020003843T5/de active Pending
- 2020-08-14 HR HRP20241255TT patent/HRP20241255T1/hr unknown
- 2020-08-14 LT LTEPPCT/US2020/046407T patent/LT4013385T/lt unknown
- 2020-08-14 ES ES20765121T patent/ES2992930T3/es active Active
- 2020-08-14 HU HUE20765121A patent/HUE068356T2/hu unknown
- 2020-08-14 CA CA3150458A patent/CA3150458A1/en active Pending
- 2020-08-14 EP EP20765121.7A patent/EP4013385B1/en not_active Revoked
- 2020-08-14 PE PE2022000237A patent/PE20220968A1/es unknown
- 2020-08-14 UA UAA202200959A patent/UA129330C2/uk unknown
- 2020-08-14 US US17/634,516 patent/US20230097090A1/en active Pending
- 2020-08-14 JP JP2022508754A patent/JP7753190B2/ja active Active
- 2020-08-14 FI FIEP20765121.7T patent/FI4013385T3/fi active
- 2020-08-14 DK DK20765121.7T patent/DK4013385T3/da active
- 2020-08-14 EP EP24185708.5A patent/EP4454640A3/en active Pending
- 2020-08-14 CR CR20220108A patent/CR20220108A/es unknown
- 2020-08-14 GE GEAP202015904A patent/GEP20257820B/en unknown
- 2020-08-14 PH PH1/2022/550363A patent/PH12022550363A1/en unknown
- 2020-08-14 GE GEAP202515904A patent/GEAP202515904A/en unknown
- 2020-08-14 BR BR112022002708A patent/BR112022002708A2/pt unknown
- 2020-08-14 SI SI202030493T patent/SI4013385T1/sl unknown
- 2020-08-14 KR KR1020227008228A patent/KR20220053599A/ko not_active Ceased
- 2020-08-14 PL PL20765121.7T patent/PL4013385T3/pl unknown
-
2022
- 2022-02-09 IL IL290477A patent/IL290477A/en unknown
- 2022-02-09 MX MX2025003983A patent/MX2025003983A/es unknown
- 2022-02-11 CL CL2022000351A patent/CL2022000351A1/es unknown
- 2022-02-13 JO JOP/2022/0037A patent/JOP20220037A1/ar unknown
- 2022-02-14 DO DO2022000038A patent/DOP2022000038A/es unknown
- 2022-03-07 CO CONC2022/0002685A patent/CO2022002685A2/es unknown
- 2022-03-11 EC ECSENADI202218209A patent/ECSP22018209A/es unknown
-
2025
- 2025-07-31 JP JP2025128566A patent/JP2025173509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544652A5 (https=) | ||
| GB2600859A (en) | Improved lipid nanoparticles for delivery of nucleic acids | |
| US12017989B2 (en) | Controlled release pharmaceutical formulations | |
| JP2018521052A5 (https=) | ||
| CN108024960B (zh) | 含有阴离子药物的药物组合物及其制备方法 | |
| US9687448B2 (en) | Nucleic acid lipid particle formulations | |
| CA2532228C (en) | Lipid encapsulated interfering rna | |
| WO2022115645A4 (en) | Lipid nanoparticles for delivery of nucleic acids, and related methods of use | |
| JP2024546950A5 (https=) | ||
| JP2011507534A5 (https=) | ||
| JP2016121174A (ja) | 活性剤の送達のための生分解性脂質 | |
| CN116813493B (zh) | 一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂 | |
| AU2016297153A1 (en) | Compositions and methods for nanoparticle lyophile forms | |
| JP2001527052A (ja) | ポリアミドオリゴマー | |
| WO2024046448A1 (en) | Lyophilized formulations and liquid formulations of lipid nanoparticles | |
| KR102758330B1 (ko) | 황화물을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
| ZA200308938B (en) | Lipid-polymer-conjugates. | |
| WO2013003306A1 (en) | Pharmaceutical compositions for parenteral administration | |
| CN120359208A (zh) | 可电离脂质及其用途 | |
| CN118632690A (zh) | 含有可生物降解的酯键的可电离脂质和包含其的脂质纳米颗粒 | |
| KR102911928B1 (ko) | 신규 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
| CN120835876A (zh) | 包括具有支化结构的电离脂质的脂质纳米粒制剂及其用途 | |
| JP2026501351A (ja) | 組成物 | |
| JP2025504682A5 (https=) | ||
| WO2004054963A1 (en) | Sphingolipid derivatives modified by polyethylene glycol and composition containing the same |